M&A

Allergan’s deal spree continues with $2.9B LifeCell buyout

Brent Saunders, CEO Allergan

Brent Saunders, CEO Allergan

Allergan isn’t letting the holidays get in the way of its deal spree. The company has snapped up LifeCell and its aesthetic and regenerative medtech for $2.9 billion in cash.

The deal gives Allergan a portfolio that includes:

  • Acellular Dermal Matrices, commonly used in breast reconstruction procedures and complex hernia surgeries to provide soft tissue support;
  • Alloderm, a human allograft tissue matrix which “allows for a strong, intact repair in challenging procedures and is intended to be used for repair or replacement of damaged or inadequate soft tissue, including breast reconstruction post-mastectomy;”
  • Revolve, a single use high-volume fat grafting device that uses patients’ own fat to enhance volume in plastic and reconstructive procedures.

The buyout also includes LifeCell’s R&D operations in New Jersey.

“The acquisition of LifeCell is both strategically and financially compelling to Allergan and serves as our entry point into regenerative medicine as we create a world-class aesthetic and regenerative medicine business in plastic surgery.  LifeCell’s regenerative medicine unit is a strong fit with our existing business and can be significantly strengthened with our infrastructure and global reach,” said Brent Saunders, Chairman and CEO of Allergan.  “This acquisition is an immediately accretive investment that enhances our near-term and long-term growth profile with products that enjoy strong sales and are the leading choices for surgeons who rely on them for successful surgical procedures.”


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy